Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model

Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model

Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer. Recently, studies proved that Gefitinib-induced cardiotoxicity through induction of oxidative stress leads to cardiac hypertroph...

Full description

Bibliographic Details
Main Authors: Wael A. Alanazi, Hussain N. Alhamami, Metab Alharbi, Khalid Alhazzani, Abdulrahman S. Alanazi, Sary Alsanea, Nemat Ali, Abdullah F. Alasmari, Ahmed Z. Alanazi, Moureq R. Alotaibi, Mohammed Alswayyed
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Saudi Pharmaceutical Journal
Subjects:
Gefitinib
angiotensin II
Cardiac hypertrophy
NADPH oxidase
MAPK
Online Access:http://www.sciencedirect.com/science/article/pii/S1319016422001670

Internet

http://www.sciencedirect.com/science/article/pii/S1319016422001670

Similar Items